| 1 |
NCT02565979 |
Recruiting |
Long-term Resveratrol and Metabolism |
|
- Dietary Supplement: resveratrol
- Dietary Supplement: placebo
|
Interventional |
Not Applicable |
- Maastricht University Medical Center
- Diabetes Fonds
- DSM Nutritional Products, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in Glucose Tolerance
- Change in Intra-hepatic lipid content
- Change in Resting energy expenditure
- (and 6 more...)
|
58 |
All |
40 Years to 70 Years (Adult, Senior) |
NCT02565979 |
15-3-037 |
|
April 2016 |
September 2018 |
December 2018 |
October 1, 2015 |
October 18, 2017 |
|
- Maastricht University and Medical Centre
Maastricht, Limburg, Netherlands
|
| 2 |
NCT03446625 |
Recruiting |
Resveratrol as a Preventive Treatment of OHSS |
|
- Drug: Resveratrol
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Serum VEGF levels
- Hemoconcentration
- Serum estradiol levels
- Ascitis
|
70 |
Female |
18 Years to 35 Years (Adult) |
NCT03446625 |
1401-MAD-004-IO |
RES-OHSS |
March 13, 2018 |
June 2018 |
September 2018 |
February 27, 2018 |
March 26, 2018 |
|
|
| 3 |
NCT03448094 |
Recruiting |
The Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation. |
- Cognitive Function and Mood
- Cerebral Blood Flow
- Systemic Inflammation
- (and 2 more...)
|
- Dietary Supplement: Resveratrol
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- Northumbria University
- Evolva SA
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Change from baseline cognitive (memory) performance at 45 minutes, 240 minutes and 12 weeks post dose
- Change from baseline cognitive (Attention) performance at 45 minutes, 240 minutes and 12 weeks post dose
- Gut microbiota
- (and 9 more...)
|
110 |
All |
35 Years to 60 Years (Adult) |
NCT03448094 |
52P6 |
|
February 6, 2018 |
October 2018 |
October 2018 |
February 27, 2018 |
February 27, 2018 |
|
- Northumbria University
Newcastle Upon Tyne, Tyne And Wear, United Kingdom
|
| 4 |
NCT01914081 |
Recruiting |
Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside |
- Non-ischemic Cardiomyopathy
|
- Other: Resveratrol
- Other: Placebo
|
Interventional |
Phase 3 |
- St. Boniface General Hospital Research Centre
- Canadian Centre for Agri-Food Research in Health and Medicine
- Agriculture and Agri-Food Canada
- Manitoba Medical Service Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Quality of life
- Cardiac Function
- Oxidative Stress
- (and 3 more...)
|
40 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01914081 |
CTA/2012/0002
RRC/2011/1169 |
|
January 2015 |
February 2018 |
November 2018 |
August 1, 2013 |
April 21, 2016 |
|
- St. Boniface General Hospital
Winnipeg, Manitoba, Canada
|
| 5 |
NCT03253913 |
Recruiting |
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial |
|
- Drug: Sirolimus
- Drug: Resveratrol
|
Interventional |
Phase 2 |
- University of Cincinnati
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in serum VEGF-D level after treatment with a combination of resveratrol and sirolimus
- Incidence of Treatment-Emergent Adverse Events
- Rate of change in Pulmonary function tests (PFTs) before and after treatment
- (and 4 more...)
|
25 |
Female |
18 Years and older (Adult, Senior) |
NCT03253913 |
2016-4904
1R34HL138235-01 |
RESULT |
March 31, 2018 |
January 30, 2020 |
June 30, 2020 |
August 18, 2017 |
March 20, 2018 |
|
- University of Cincinnati
Cincinnati, Ohio, United States
|
| 6 |
NCT02905799 |
Recruiting |
Resveratrol in Knee Osteoarthritis |
|
- Drug: oral resveratrol
- Drug: oral placebo
|
Interventional |
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
- Unité de Recherche Clinique (URC) Paris Descartes Cochin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Mean change from baseline in knee pain in the previous 48 hours
- Mean change from baseline in specific activity limitation
- Mean change from baseline in patient's global assessment
- (and 4 more...)
|
164 |
All |
40 Years and older (Adult, Senior) |
NCT02905799 |
P150938
2016-A01310-51 |
ARTHROL |
November 9, 2017 |
February 2020 |
August 2020 |
September 19, 2016 |
December 8, 2017 |
|
- Rehabilitation department , CHU Clermont-Ferrand
Cebazat, France - Rheumatology Department, Saint Antoine Hospital
Paris, France - Rehabilitation Department, Cochin Hospital
Paris, France
|
| 7 |
NCT02625376 |
Recruiting |
Resveratrol for Exudative Age-Related Macular Degeneration |
- AMD
- Age-related Macular Degeneration
- Choroidal Neovascularisation
|
- Dietary Supplement: Resvega
- Dietary Supplement: Trans-Resveratrol
- Dietary Supplement: placebo
|
Interventional |
Not Applicable |
- Poitiers University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months
- Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months
|
489 |
All |
55 Years and older (Adult, Senior) |
NCT02625376 |
AGED/EudraCT : 2015-001577-41 |
AGED |
August 2015 |
June 2019 |
August 2019 |
December 9, 2015 |
May 24, 2016 |
|
- CHU de Poitiers - Ophtalmology
Poitiers, France
|
| 8 |
NCT03384329 |
Recruiting |
Efficacy of Resveratrol in Depression |
|
- Drug: Resveratrol Pill
- Drug: Placebos
|
Interventional |
Phase 4 |
- Russian Academy of Medical Sciences
- Russian Science Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline total score of HDRS-17
- Change from baseline SIRT1 enzymatic activity in the blood
- Change from baseline total score of HDRS-SR-17
|
60 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03384329 |
RESV-depression |
|
January 2018 |
December 2018 |
February 2019 |
December 27, 2017 |
January 4, 2018 |
|
- Konstantin V. Danilenko
Novosibirsk, Russian Federation
|
| 9 |
NCT03090997 |
Recruiting |
Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women |
- Postmenopausal
- Insulin Resistance
|
- Dietary Supplement: vitamin C (500 mg / day) + placebo
- Dietary Supplement: resveratrol (500 mg / day) + placebo
- Dietary Supplement: vitamin C (500 mg / day) and resveratrol (500 mg / day)
|
Interventional |
Not Applicable |
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Insulin resistance
- Superoxide dismutase activity
- Catalase activity
- (and 4 more...)
|
270 |
Female |
50 Years to 60 Years (Adult) |
NCT03090997 |
3210-10209-01-574-17 |
|
February 15, 2018 |
November 30, 2019 |
August 20, 2020 |
March 27, 2017 |
March 1, 2018 |
|
- Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Mexico City, Mexico
|
| 10 |
NCT03349619 |
Recruiting |
Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis |
|
- Drug: Resveratrol plus Carboxymethyl-β-Glucan
- Drug: Placebo
|
Interventional |
Phase 4 |
- Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Nasal Interleukin-5 (IL-5)
- Total 5 Symptom Score (T5SS)
- Visual Analogue Scale for Rhinitis (VAS)
- (and 6 more...)
|
88 |
All |
6 Years to 16 Years (Child) |
NCT03349619 |
10/2017 |
RENIM |
March 5, 2018 |
December 31, 2018 |
December 31, 2018 |
November 21, 2017 |
March 13, 2018 |
|
- Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo
Palermo, Italy
|
| 11 |
NCT02947932 |
Not yet recruiting |
Oral Resveratrol to Prevent Post-ERCP Pancreatitis |
- Pancreatitis, Acute
- Gastrointestinal Disease
|
- Drug: Resveratrol
- Drug: Indomethacin
|
Interventional |
Phase 4 |
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Post-ERCP Pancreatitis
- Moderate-to-severe Pancreatitis
|
2700 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02947932 |
XJTU1AFCT-2016-007 |
|
December 2016 |
March 2018 |
September 2018 |
October 28, 2016 |
October 28, 2016 |
|
|
| 12 |
NCT02766803 |
Recruiting |
Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients |
|
- Drug: Simvastatin and micronized trans-resveratrol
|
Interventional |
Phase 4 |
- Poznan University of Medical Sciences
- University of California, San Diego
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- testosterone serum concentration
|
60 |
Female |
18 Years to 45 Years (Adult) |
NCT02766803 |
PoznanUMS 3 |
|
May 2016 |
June 2017 |
June 2018 |
May 10, 2016 |
September 8, 2016 |
|
- Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obsterics
Poznan, Poland
|
| 13 |
NCT02123121 |
Recruiting |
Resveratrol to Enhance Vitality and Vigor in Elders |
- Mitochondrial Function
- Physical Function
|
- Drug: Resveratrol 1000 mg/day
- Drug: Resveratrol 1500 mg/day
- Other: Vegetable cellulose
- Other: All groups
|
Interventional |
Phase 2 |
- University of Florida
- National Center for Complementary and Integrative Health (NCCIH)
- Office of Dietary Supplements (ODS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Change from Baseline in mitochondrial respiration in muscle
- Change from baseline in cytochrome oxidase (COX) in muscle samples
- Change from baseline in citrate synthase (CS) enzymes in muscle samples
- (and 11 more...)
|
60 |
All |
65 Years and older (Adult, Senior) |
NCT02123121 |
IRB201400439 -A N
1R01AT007564-01 |
REVIVE |
September 2015 |
May 2019 |
May 2019 |
April 25, 2014 |
April 6, 2018 |
|
- UF Institute on Aging Clinical and Translational Research Building
Gainesville, Florida, United States
|
| 14 |
NCT02523274 |
Recruiting |
Resveratrol and Exercise to Treat Functional Limitations in Late Life |
|
- Drug: Resveratrol
- Drug: Placebo
- Behavioral: Exercise
|
Interventional |
Phase 2 |
- University of Florida
- National Institute on Aging (NIA)
- University of Alabama at Birmingham
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Walking Speed changes between the groups at baseline, 6, and 12 weeks.
- Short Physical Performance Battery (SPPB) changes between the groups at baseline, 6, and 12 weeks.
- Skeletal Muscle Function assessed by a dynamometer will demonstrate changes between the groups at baseline, 6, and 12 weeks.
- (and 2 more...)
|
60 |
All |
65 Years and older (Adult, Senior) |
NCT02523274 |
IRB201500598 -N
R21AG049974 |
|
June 2016 |
May 2018 |
May 2018 |
August 14, 2015 |
April 5, 2018 |
|
- UAB Center for Exercise Medicine
Birmingham, Alabama, United States
|
| 15 |
NCT02336633 |
Recruiting |
Resveratrol and Huntington Disease |
|
- Dietary Supplement: Resveratrol
- Other: Placebo
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- rate of caudate atrophy
- UHDRS (Unified Huntington Disease Rating Scale)
- TFC (Total Functional Capacity)
- ratio of inorganic phosphate/phosphocreatine
|
102 |
All |
18 Years and older (Adult, Senior) |
NCT02336633 |
P130918 |
REVHD |
July 2015 |
January 2019 |
January 2019 |
January 13, 2015 |
April 17, 2018 |
|
- Institut du Cerveau et de la Moelle, Hôpital de la Pitié Salpêtrière
Paris, France
|
| 16 |
NCT01842399 |
Recruiting |
Resveratrol and Cardiovascular Health in the Elderly |
- Vascular Resistance
- Aging
- Hypertension
- (and 2 more...)
|
- Dietary Supplement: Resveratrol
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- National Institute on Aging (NIA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
|
- Decreased rate of age associated arterial stiffening
- Changes in aerobic capacity, functional capacity, body composition, muscle energetics, inflammatory markers, glucose metabolism.
|
300 |
All |
50 Years to 100 Years (Adult, Senior) |
NCT01842399 |
130078
13-AG-0078 |
|
February 9, 2013 |
September 1, 2018 |
September 1, 2018 |
April 29, 2013 |
March 21, 2018 |
|
- National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, United States
|
| 17 |
NCT02909699 |
Recruiting |
Cardiovascular Health of Older Adults and Resveratrol (CORE) |
|
|
Observational |
|
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Speckle tracking analyses
- Flow-mediated dilation
- Autophagy measured by Enzyme-linked immunosorbent assay (ELISA)
- (and 5 more...)
|
45 |
All |
65 Years to 99 Years (Adult, Senior) |
NCT02909699 |
IRB201601756 |
CORE |
November 2016 |
September 2018 |
September 2018 |
September 21, 2016 |
December 21, 2017 |
|
- University of Florida
Gainesville, Florida, United States
|
| 18 |
NCT02502253 |
Recruiting |
BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM) |
- Mild Cognitive Impairment
- Alzheimer's Disease
|
- Drug: grape seed polyphenolic extract, resveratrol
|
Interventional |
Phase 1 |
- Johns Hopkins University
- Icahn School of Medicine at Mount Sinai
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Assessment of Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Confirm brain penetrance of BDPP by measuring levels of BDPP constituents in cerebrospinal fluid (CSF).
- Evaluate BDPP effect on mood with Neuropsychiatric Inventory and Cornell Scale for Depression in Dementia.
- Evaluate BDPP effect on cognition with a composite battery of memory, executive function, and attention measures (composite)
|
48 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT02502253 |
IRB00062802 |
BDPP |
June 2015 |
June 2018 |
October 2018 |
July 20, 2015 |
October 27, 2017 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
| 19 |
NCT03436992 |
Recruiting |
Estrogen and Diabetes |
- Diabetes Mellitus, Type 1
|
- Dietary Supplement: Antioxidant Cocktail
- Dietary Supplement: Resveratrol
- Other: Placebo
|
Interventional |
Not Applicable |
- Augusta University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Flow-Mediated Dilation (FMD)
|
198 |
All |
18 Years to 40 Years (Adult) |
NCT03436992 |
E2 and D
1R01HL137087-01A1 |
|
April 17, 2018 |
May 1, 2024 |
May 1, 2024 |
February 19, 2018 |
April 19, 2018 |
|
- Augusta University
Augusta, Georgia, United States - Georgia Prevention Institute
Augusta, Georgia, United States
|
| 20 |
NCT02998918 |
Recruiting |
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL |
- Inflammation
- Atherosclerosis
- Cardiovascular Disease
|
- Dietary Supplement: PolyResveratrol Supplementation
- Dietary Supplement: Curcumin Supplementation
|
Interventional |
Phase 2 |
- University of South Carolina
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Inflammation change: Whole plasma
- Inflammation change: HDL plasma
- Cholesterol efflux capacity
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT02998918 |
COBRE PSI |
PSI |
September 2016 |
October 2018 |
December 2018 |
December 21, 2016 |
November 17, 2017 |
|
- Clinical Exercise Research Center
Columbia, South Carolina, United States
|
| 21 |
NCT02633150 |
Recruiting |
Assessing the Value of Red Grapes Polyphenol Supplementation on Metabolic Parameters in Obese Insulinoresistant Subjects |
- Obesity
- Insulin Resistance
- Menopause
|
- Other: Supplementation with red grapes polyphenol
|
Interventional |
Not Applicable |
- University Hospital, Montpellier
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Measure of systemic insulin sensitivity (estimated by GIR :rate glucose infusion) measured by hyperinsulinemic-euglycemic clamp
- Measure of insulin sensitivity to tissue (fat and muscle by measure ratio phosphoAKT/AKT measured by Western BLOT) before and after the supplementation
- Measure of systemic concentration (by Multiplex)
|
46 |
All |
50 Years to 65 Years (Adult) |
NCT02633150 |
9501
2014-A01627-40 |
POLYGIR |
October 2015 |
April 2017 |
June 2017 |
December 17, 2015 |
December 8, 2016 |
|
- CHU Montpellier - Lapeyronie hospital
Montpellier, France
|
| 22 |
NCT02909686 |
Recruiting |
Effects of Botanical Microglia Modulators in Gulf War Illness |
|
- Dietary Supplement: Boswellia Serrata
- Dietary Supplement: Curcumin
- Dietary Supplement: Epimedium
- (and 7 more...)
|
Interventional |
Not Applicable |
- University of Alabama at Birmingham
- Congressionally Directed Medical Research Programs
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Change from baseline in overall Gulf War Illness disease severity
- Change from baseline in Pain Severity
- Change from baseline in Fatigue Severity
- (and 5 more...)
|
40 |
Male |
39 Years to 65 Years (Adult) |
NCT02909686 |
F150318011
CDMRP-GW130015 |
|
July 2016 |
September 2019 |
September 2019 |
September 21, 2016 |
August 15, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
Create an RSS feed from your search for:
Download the search results for: